Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Wet AMD: Frequency of Dosing and Impact on Patient Outcomes

By: Arshad M. Khanani, MD, MA; and Diana V. Do, MD

Webinar Credits: .5

This program, featuring Arshad M. Khanani, MD, MA; and Diana V. Do, MD, highlights how dosing frequency for the treatment of wet AMD is changing based on pivotal clinical trials and real-world experience. They also discuss how the evolving treatment regimens may improve patient outcomes and help overcome challenges faced by patients and retina specialists with monthly dosing.

Expiration Date: Monday, May 31, 2021
Release Date: May 29, 2020

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
  • Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
  • Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.

 

 

Accreditation and Designation Statement

Provided by Evolve Medical Education 

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

 

Faculty and Disclosures

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Reno, Nevada

Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, California

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Arshad M. Khanani, MD, MA, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Adverum Biotechnologies, Allegro, Allergan, Bausch + Lomb, Eyepoint, Graybug, Gemini, Genentech, Gyroscope, Kodiak Sciences, Novartis, Opthea, Oxurion, Polyphotonix, Recens Medical, and Regenxbio. Grant/Research Support: Adverum Biotechnologies, Allergan, Gemini, Genentech, Graybug, Gyroscope, IVERIC Bio, Kodiak Sciences, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau: Allergan, and Novartis.

Diana Do, MD, and or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Kodiak Sciences, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Novartis, Regeneron Pharmaceuticals, and Santen.

Editorial Disclosures

The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech.

Pretest

  • 1 Not at all confident2 Not very confident3 Neutral4 Confident5 Very confident

Video Resources

Next

Test

Instructions

Step 1 of 2

50%
  • 1 Not at all confident2 Not very confident3 Neutral4 Confident5 Very confident
  • AgreeNeutralDisagree
    Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
    Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
    Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.
Back